Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Diisopyramide
2. Disopyramide
3. Disopyramide Monohydrochloride
4. Disopyramide Phosphate (1:1)
5. Disopyramide Phosphate (1:1), (+-)-isomer
6. Disopyramide Phosphate (1:1), (r)-isomer
7. Disopyramide Phosphate (1:1), (s)-isomer
8. Disopyramide, (+-)-isomer
9. Disopyramide, (r)-isomer
10. Disopyramide, (s)-isomer
11. Disopyramide, D-tartrate (1:1), (s)-isomer
12. Disopyramide, L-tartrate (1:1), (r)-isomer
13. Disopyramide, L-tartrate (1:1), (s)-isomer
14. Disopyramide, L-tartrate (1:2), (+-)-isomer
15. Disopyramide, L-tartrate, (s)-isomer
16. Norpace
17. Palpitin
18. Palpitine
19. Rhythmodan
20. Ritmilen
21. Rythmilen
22. Sc 13957
23. Sc-13957
24. Sc13957
1. 22059-60-5
2. Norpace
3. Disopyramide Phosphate Salt
4. Rythmodan
5. Norpace Cr
6. Sc 7031 Phosphate
7. Dirythmin Sa
8. Diso-duriles
9. Disopyramidephosphate
10. Einecs 244-756-1
11. Sc 7031 (phosphate)
12. Nsc-756744
13. Sc-13957
14. Sc-7031 Phosphate
15. Chebi:4658
16. N6bom1935w
17. 22059-60-5 (phosphate)
18. 2-(1-(ammoniocarbonyl)-3-(diisopropylammonio)-1-phenylpropyl)pyridinium Phosphate
19. Disopyramid Phosphate
20. 4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide Phosphate
21. Sr-01000003039
22. Norpace (tn)
23. Sc 13957
24. Disopyramide (phosphate)
25. Unii-n6bom1935w
26. Schembl41810
27. Mls000028431
28. Spectrum1500261
29. Chembl1201020
30. Hms501i11
31. Dtxsid30944685
32. Disopyramide Phosphate (jan/usp)
33. Hms1920i14
34. Hms2094k15
35. Hms2234b16
36. Hms3259j21
37. Hms3261c04
38. Hms3369l05
39. Hms3652m20
40. Hms3885j07
41. Pharmakon1600-01500261
42. Disopyramide Phosphate [mi]
43. Xaa05960
44. Disopyramide Phosphate [jan]
45. Tox21_500411
46. Ccg-40209
47. Disopyramide Phosphate [usan]
48. Hy-12533a
49. Nsc756744
50. Disopyramide Phosphate [vandf]
51. 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide;phosphoric Acid
52. Alpha-(2-diisopropylaminoethyl)-alpha-phenyl-2-pyridineacetamide Phosphate
53. Disopyramide Phosphate [mart.]
54. Disopyramide Phosphate [usp-rs]
55. Disopyramide Phosphate [who-dd]
56. Lp00411
57. Nc00683
58. Nsc 756744
59. (+-)-alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide Phosphate (1:1)
60. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, Phosphate
61. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, Phosphate (1:1)
62. 2-pyridineacetamide, Alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-, Phosphate
63. Alpha-(2-(diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide Phosphate (1:1)
64. Ncgc00093836-01
65. Ncgc00093836-02
66. Ncgc00093836-03
67. Ncgc00093836-04
68. Ncgc00261096-01
69. 2-pyridineacetamide, Alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-, (+-)-, Phosphate (1:1)
70. Smr000058438
71. Db-045779
72. Disopyramide Phosphate [orange Book]
73. Disopyramide Phosphate [ep Monograph]
74. Disopyramide Phosphate [usan:usp:ban:jan]
75. Eu-0100411
76. Ft-0630479
77. S4143
78. Sw196836-3
79. Sw196836-4
80. Disopyramide Phosphate [usp Monograph]
81. C07740
82. D 6035
83. D00637
84. Sr-01000003039-2
85. Sr-01000003039-6
86. Q27106430
87. 4-(diisopropylamino)-2-phenyl-2-(2-pyridyl)butanamide
88. (r)-4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide Phosphate
89. 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide,phosphoric Acid
90. 4-diisopropylamino-2-phenyl-2-(2-pyridyl)butyramide Phosphate
91. Disopyramide Phosphate, European Pharmacopoeia (ep) Reference Standard
92. Disopyramide Phosphate, United States Pharmacopeia (usp) Reference Standard
93. (+/-)-.alpha.-(2-(diisopropylamino)ethyl)-.alpha.-phenyl-2-pyridineacetamide Phosphate (1:1)
94. 2-pyridineacetamide, .alpha.-(2-(bis(1-methylethyl)amino)ethyl)-.alpha.-phenyl-, (+/-)-, Phosphate (1:1)
Molecular Weight | 437.5 g/mol |
---|---|
Molecular Formula | C21H32N3O5P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 437.20795813 g/mol |
Monoisotopic Mass | 437.20795813 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 459 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Disopyramide phosphate |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Disopyramide Phosphate is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of Diso... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Watson Labs; Teva |
2 of 6 | |
---|---|
Drug Name | Norpace |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
3 of 6 | |
---|---|
Drug Name | Norpace cr |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phos... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
4 of 6 | |
---|---|
Drug Name | Disopyramide phosphate |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Disopyramide Phosphate is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of Diso... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Watson Labs; Teva |
5 of 6 | |
---|---|
Drug Name | Norpace |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
6 of 6 | |
---|---|
Drug Name | Norpace cr |
PubMed Health | Disopyramide (By mouth) |
Drug Classes | Antiarrhythmic, Group IA |
Drug Label | Norpace (disopyramide phosphate) is an antiarrhythmic drug available for oral administration in immediate-release and controlled-release capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phos... |
Active Ingredient | Disopyramide phosphate |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | eq 100mg base; eq 150mg base |
Market Status | Prescription |
Company | Gd Searle |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Disopyramide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Disopyramide, including repackagers and relabelers. The FDA regulates Disopyramide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Disopyramide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Disopyramide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Disopyramide supplier is an individual or a company that provides Disopyramide active pharmaceutical ingredient (API) or Disopyramide finished formulations upon request. The Disopyramide suppliers may include Disopyramide API manufacturers, exporters, distributors and traders.
click here to find a list of Disopyramide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Disopyramide DMF (Drug Master File) is a document detailing the whole manufacturing process of Disopyramide active pharmaceutical ingredient (API) in detail. Different forms of Disopyramide DMFs exist exist since differing nations have different regulations, such as Disopyramide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Disopyramide DMF submitted to regulatory agencies in the US is known as a USDMF. Disopyramide USDMF includes data on Disopyramide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Disopyramide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Disopyramide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Disopyramide Drug Master File in Japan (Disopyramide JDMF) empowers Disopyramide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Disopyramide JDMF during the approval evaluation for pharmaceutical products. At the time of Disopyramide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Disopyramide suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Disopyramide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Disopyramide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Disopyramide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Disopyramide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Disopyramide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Disopyramide suppliers with NDC on PharmaCompass.
Disopyramide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Disopyramide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Disopyramide GMP manufacturer or Disopyramide GMP API supplier for your needs.
A Disopyramide CoA (Certificate of Analysis) is a formal document that attests to Disopyramide's compliance with Disopyramide specifications and serves as a tool for batch-level quality control.
Disopyramide CoA mostly includes findings from lab analyses of a specific batch. For each Disopyramide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Disopyramide may be tested according to a variety of international standards, such as European Pharmacopoeia (Disopyramide EP), Disopyramide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Disopyramide USP).
LOOKING FOR A SUPPLIER?